Improving antithrombotic treatment in patients after myocardial infarction

Lancet

Volumn 362, Issue 9386, 2003, Pages 757-

  Giugliano, Robert P ^a   Braunwald, Eugene ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; MELAGATRAN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

BLEEDING; CLINICAL TRIAL; COMMERCIAL PHENOMENA; DNA POLYMORPHISM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FETUS MALFORMATION; GENETIC CODE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; LIVER DYSFUNCTION; NOTE; PATIENT; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 0041829449     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14296-1     Document Type: Note

References (9)

1. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 324:2002;71-86.
2. Hurlen M., Abdelnoor M., Smith P., Erikssen J., Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 347:2002;969-974.
3. van Es R.F., Jonker J.J., Verheugt F.W., Deckers J.W., Grobbee D.E. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 360:2002;109-113.
4. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 348:1996;1329-1339.
5. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 345:2001;494-502.
6. Weitz J.I., Hirsh J. New anticoagulant drugs. Chest. 119:(suppl 1):2001;95S-107S.
7. Kaplan K.L., Francis C.W. Direct thrombin inhibitors. Semin Hematol. 39:2002;187-196.
8. Furuya H., Fernandez-Salguero P., Gregory W., et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics. 5:1995;389-392.
9. Oldenburg J., Quenzel E.M., Harbrecht U., et al. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol. 98:1997;240-244.